Early Management of Acute Ischemic Stroke: Focus on IV tPA and Timely Reperfusion

Authors

Viet-Hong Nguyen, Chapman UniversityFollow
Bonnie M. Wong, University of Southern California
Diana D. Shen, University of Southern California
Denny T. Woo, University of Southern California
Amanda V. Vu, University of Southern California
Janette D. Lie, University of Southern California

Document Type

Article

Publication Date

1-20-2016

Abstract

Alteplase (Activase), an intravenous (IV) tissue plasminogen activator (tPA), is the only FDA-approved thrombolytic agent for acute ischemic stroke (AIS). Recently updated American Heart Association/American Stroke Association (AHA/ASA) Guidelines for the Early Management of Patients with Acute Ischemic Stroke and revisions to Activase labeling have expanded the time window eligibility for tPA treatment and have loosened contraindications surrounding tPA treatment. These changes should promote increased utilization of tPA in AIS, resulting in more instances of timely reperfusion and reduction of neurologic sequelae.

Comments

This article was originally published in US Pharmacist, volume 41, issue 1, in 2016.

Recommended Citation

Nguyen, VV, Wong BM, Shen DD, Woo DT, Vu AV, Lie JD. Early management of acute ischemic stroke: focus on IV tPA and timely reperfusion. US Pharm. 2016;41(1):HS9-H12. http://www.uspharmacist.com/content/c/59017/.

Copyright

Jobson Medical Information LLC